Geode Capital Management LLC Buys 1,163,575 Shares of Dr. Reddy's Laboratories Limited (NYSE:RDY)

Geode Capital Management LLC lifted its stake in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 8,779.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,176,829 shares of the company's stock after acquiring an additional 1,163,575 shares during the period. Geode Capital Management LLC owned approximately 0.14% of Dr. Reddy's Laboratories worth $18,582,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Public Employees Retirement System of Ohio bought a new position in Dr. Reddy's Laboratories during the 3rd quarter worth about $464,000. Virtu Financial LLC acquired a new position in shares of Dr. Reddy's Laboratories during the third quarter worth about $276,000. World Investment Advisors LLC bought a new position in shares of Dr. Reddy's Laboratories during the third quarter worth about $3,459,000. B. Riley Wealth Advisors Inc. acquired a new stake in Dr. Reddy's Laboratories in the 3rd quarter valued at approximately $490,000. Finally, Confluence Investment Management LLC lifted its stake in Dr. Reddy's Laboratories by 400.0% in the 4th quarter. Confluence Investment Management LLC now owns 18,290 shares of the company's stock valued at $289,000 after acquiring an additional 14,632 shares in the last quarter. 3.85% of the stock is currently owned by institutional investors and hedge funds.

Dr. Reddy's Laboratories Price Performance

Shares of RDY opened at $13.69 on Friday. The company has a quick ratio of 1.38, a current ratio of 1.92 and a debt-to-equity ratio of 0.02. Dr. Reddy's Laboratories Limited has a twelve month low of $12.26 and a twelve month high of $16.89. The stock has a market capitalization of $11.42 billion, a P/E ratio of 21.79 and a beta of 0.51. The company has a 50 day moving average of $13.16 and a 200-day moving average of $14.28.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last released its earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share for the quarter, beating analysts' consensus estimates of $0.19 by $0.01. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. As a group, equities research analysts forecast that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current fiscal year.

Dr. Reddy's Laboratories Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.

Want to see what other hedge funds are holding RDY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.